Shou Yun Yin

CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition

Stephen J. Morris, D. Durocher, R. Stocco, 2022, Nature.

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors

R. Stocco, A. Roulston, Jordan T. F. Young, 2021, Molecular Cancer Therapeutics.

CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition

D. Durocher, R. Stocco, A. Roulston, 2021, Nature.

The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer

Toshiro K. Ohsumi, D. Durocher, Jordan T. F. Young, 2021, Nature Cancer.

Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.

R. Stocco, F. Sicheri, P. Beaulieu, 2022, Journal of medicinal chemistry.

CIP2A is a prime synthetic-lethal target for BRCA-mutated cancers

Toshiro K. Ohsumi, D. Durocher, Jordan T. F. Young, 2021, bioRxiv.